A randomized, placebo-controlled, double-blind, prospective trial to evaluate the effect of vildagliptin in new-onset diabetes mellitus after kidney transplantation
<p>Abstract</p> <p>Background</p> <p>New-onset diabetes mellitus after transplantation (NODAT), a frequent and serious complication after transplantation, is associated with decreased graft and patient survival. Currently, it is diagnosed and treated primarily according...
Main Authors: | Hörl Walter H, Döller Dominik, Stemer Gunar, Hecking Manfred, Pleiner Johannes, Voigt Hans-Christian, Werzowa Johannes, Haidinger Michael, Weichhart Thomas, Säemann Marcus D |
---|---|
Format: | Article |
Language: | English |
Published: |
BMC
2010-10-01
|
Series: | Trials |
Online Access: | http://www.trialsjournal.com/content/11/1/91 |
Similar Items
-
Blood volume-monitored regulation of ultrafiltration in fluid-overloaded hemodialysis patients: study protocol for a randomized controlled trial
by: Hecking Manfred, et al.
Published: (2012-06-01) -
Heart Failure with Preserved and Reduced Ejection Fraction in Hemodialysis Patients: Prevalence, Disease Prediction and Prognosis
by: Marlies Antlanger, et al.
Published: (2017-04-01) -
A randomized controlled trial-based algorithm for insulin-pump therapy in hyperglycemic patients early after kidney transplantation.
by: Johannes M Werzowa, et al.
Published: (2018-01-01) -
Vildagliptin: the known and unknown
by: L. Y. Morgunov
Published: (2016-12-01) -
Budget impact of vildagliptin
by: Orietta Zaniolo, et al.
Published: (2008-09-01)